Multiple myeloma and immunosecretory disorders: An update

Advances in Anatomic Pathology

Volumn 15, Issue 4, 2008, Pages 196-210

  Shaheen, Saad P ^a   Talwalkar, Sameer S ^b   Medeiros, L Jeffrey ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

MGUS; Multiple myeloma; Nonamyloidotic monoclonal immune deposition diseases; Plasmacytoma; Primary amyloidosis

Indexed keywords

ANTIINFECTIVE AGENT; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; M PROTEIN; PARAPROTEIN; IMMUNOGLOBULIN G;

AMYLOIDOSIS; BLOOD; BLOOD SMEAR; BONE DESTRUCTION; BONE MARROW; BONE MARROW BIOPSY; CANCER RADIOTHERAPY; CELL PROLIFERATION; CELL STRUCTURE; CHROMOSOME ABERRATION; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; EPIDEMIOLOGICAL DATA; FLOW CYTOMETRY; HEAVY CHAIN DISEASE; HISTOLOGY; HUMAN; IMMUNOGLOBULIN DEPOSITION; IMMUNOGLOBULIN PRODUCTION; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOLOGY; IMMUNOPHENOTYPING; IMMUNOPROLIFERATIVE SMALL INTESTINAL DISEASE; IMMUNOSECRETORY DISORDER; INDOLENT MULTIPLE MYELOMA; LABORATORY TEST; LYMPH NODE BIOPSY; MOLECULAR GENETICS; MONOCLONAL IMMUNOGLOBULINEMIA; MU HEAVY CHAIN DISEASE; MULTIPLE MYELOMA; MYELOMA; NONSECRETORY MYELOMA; ORGAN INJURY; OSTEOMYELITIS; PATHOLOGIST; PLASMA CELL; PLASMA CELL LEUKEMIA; PLASMACYTOMA; POEMS SYNDROME; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SMOLDERING MULTIPLE MYELOMA; TISSUE INJURY; WALDENSTROEM MACROGLOBULINEMIA; WORLD HEALTH ORGANIZATION; CLASSIFICATION; IMMUNOLOGY; METABOLISM; PARAPROTEINEMIA; PATHOLOGY;

HUMANS; IMMUNOGLOBULIN G; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PLASMA CELLS; PLASMACYTOMA; WALDENSTROM MACROGLOBULINEMIA; WORLD HEALTH ORGANIZATION;

EID: 48049111822     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e31817cfcd6     Document Type: Review

References (68)

1. Foucar K, ed. Immunosecretory disorders. Bone Marrow Pathology. 2nd ed. Chicago, IL: ASCP Press; 2001:407-433.
2. Grogan TM, VanCamp B, Kyle RA, et al. Plasma cell neoplasms. In: Jaffe ES, Harris NL, Stein H, et al, eds. World Health Organization Classification of Tumours: Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001: 142-156.
3. Munshi NC, Anderson KC. Plasma cell neoplasms. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2005:2155-2188.
4. Davies F, Anderson K. Abnormalities in immunoglobulin synthesizing cells. In: Wickramasinghe SN, McCullough J, eds. Blood and Bone Marrow Pathology. 1st ed. Philadelphia, PA: Churchill Livingstone; 2003:437-470.
5. Zubler RH. Key differentiation steps in normal B cells and in myeloma cells. Semin Hematol. 1997;34(suppl 1):13-22.
6. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
7. Singer CRJ. ABC of clinical haematology: multiple myeloma and related conditions. Br Med J. 1997;314:960-963.
8. Larson RS, Sukpanichnant S, Greer JP, et al. The spectrum of multiple myeloma: diagnostic and biological implications. Hum Pathol. 1997;28:1336-1347.
9. Kyle RA. Plasma cell disorders. In: Goldman L, Ausiello D, eds. Cecil's Textbook of Medicine. 22nd ed. Philadelphia, PA: Saunders; 2004:1184-1195.
10. Grogan TM, Spier CM. The B-cell immunoproliferative disorders, including multiple myeloma and amyloidosis. In: Knowles DM, ed. Neoplastic Hematopathology. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001:1557-1587.
11. Zulian GB. Multiple myeloma: clinical evaluation of plasma cell lymphoproliferative disorders and initial management. Semin Hematol. 1997;34:29-39.
12. Linet MS, Harlow SD, McLaughlin JK. A case-control study of multiple myeloma in whites: chronic antigenic stimulation, occupation, and drug use. Cancer Res. 1987;47:2978-2981.
13. Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic bomb survivors. Part III: Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res. 1994;137:S68-S97.
14. Hatcher JL, Baris D, Olshan AF, et al. Diagnostic radiation and the risk of multiple myeloma (United States). Cancer Causes Control. 2001;12:755-761.
15. Said JW, Rettig MR, Heppner K, et al. Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma. Blood. 1997;90: 4278-4282.
16. Tedeschi R, Luostarinen T, DePaoli P, et al. Joint Nordic prospective study on human herpesvirus 8 and multiple myeloma risk. Br J Cancer. 2005;93:834-837.
17. Brown LM, Gridley G, Pottern LM, et al. Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States. Cancer Causes Control. 2001;12:117-125.
18. Larsson SC, Wolk A. Body mass index and risk of multiple myeloma: a meta-analysis. Int J Cancer. 2007;121:2512-2516.
19. Brunning RD, McKenna RW. Plasma cell dyscrasias and related disorders. In: Rosai J, Sobin LH, eds. Atlas of Tumor Pathology: Tumors of the Bone Marrow. 3rd Series, Fascicle 9. Washington, DC: Armed Forces Institute of Pathology; 1994: 323-365.
20. Nowakowski GS, Witzig TE, Dingli D, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood. 2005; 106:2276-2279.
21. Glantz L, Rintels P, Samoszuk M, et al. Plasma cell myeloma associated with eosinophilia. Am J Clin Pathol. 1995;103: 583-587.
22. Eyden BP, Banerjee SS. Multiple myeloma showing signet-ring cell change. Histopathology. 1990;17:170-172.
23. Zukerberg LR, Ferry JA, Conlon M, et al. Plasma cell myeloma with cleaved, multilobated, and monocytoid nuclei. Am J Clin Pathol. 1990;93:657-661.
24. Greipp PR, Leong T, Bennett JM, et al. Plasmablastic morphology: an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998;91:2501-2507.
25. Feller AC, Diebold J. Plasma cell proliferations. Histopathology of Nodal and Extranodal Non-Hodgkin's Lymphomas (Based on the WHO Classification). Berlin, Germany: Springer-Verlag; 2004: 364-378.
26. Zervas K, Constantinou N, Karakantza M, et al. Anaplastic myeloma. Leuk Lymphoma. 1995;16:515-518.
27. Pillay GS, Jacobs P. Crystalline cytoplasmic inclusions in myeloma. Arch Pathol Lab Med. 1994;118:1169-1170.
28. Ridley RC, Ziao H, Hata H, et al. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood. 1993;81:767-774.
29. Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23: 3412-3420.
30. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64: 1546-1558.
31. Hideshima T, Bergsagel PL, Kuehl WM, et al. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104: 607-618.
32. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23: 6333-6338.
33. Fonseca R, San Miguel J. Prognostic factors and staging in multiple myeloma. Hematol Oncol Clin North Am. 2007;21: 1115-1140.
34. Dispenzieri A, Rajkumar SV, Gertz MA, et al. Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement. Mayo Clin Proc. 2007;82:323-341.
35. Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276-2284.
36. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032-1037.
37. Saccaro S, Fonseca R, Veillon DM, et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol. 2005;78:288-294.
38. Johnson MR, Del Carpio-Jayo D, Lin P, et al. Primary plasma cell leukemia: morphologic, immunophenotypic and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation. Ann Diagn Pathol. 2006;10:263-268.
39. Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am. 1999;13:1259-1272.
40. Avet-Loiseau H, Garand R, Lode L, et al. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003;101:1570-1571.
41. Bradwell AR, ed. Multiple myeloma. Serum Free Light Chain Analysis. 2nd ed. Birmingham, UK: The Binding Site, Ltd; 2004: 63-106.
42. Gerardi RK, Belec L, Soubrier M, et al. Overproduction of proinflammatory cytokines imbalanced by their antagonists in POEMS syndrome. Blood. 1996;87:1458-1465.
43. Rose C, Zandecki M, Copin MC, et al. POEMS syndrome: report on six patients with unusual clinical signs, elevated levels of cytokines, macrophage involvement and chromosomal aberrations of bone marrow plasma cells. Leukemia. 1997;11:1318-1323.
44. Belec L, Mohamed AS, Authier F-J, et al. Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman's disease. Blood. 1999;93:3643-3653.
45. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101:2496-2506.
46. Kastritis E, Terpos E, Anagnostopoulos A, et al. Angiogenic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous stem cell support. Clin Lymphoma Myeloma. 2006;7:73-76.
47. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569.
48. Kyle RA. "Benign" monoclonal gammopathy - after 20 to 35 years of follow-up. Mayo Clin Proc. 1993;68:26-36.
49. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362-1369.
50. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo clinic series 25 years later. Mayo Clin Proc. 2004;79:859-866.
51. Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356:2582-2590.
52. Alexiou C, Kau RJ, Dietzfelbinger H, et al. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer. 1999;85:2305-2314.
53. Buxbaum J. Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. Hematol Oncol Clin North Am. 1992;6:323-346.
54. Buxbaum J, Gallo G. Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematol Oncol Clin North Am. 1999;13:1235-1248.
55. Gallo G, Goni F, Boctor F, et al. Light chain cardiomyopathy. Structural analysis of the light chain tissue deposits. Am J Pathol. 1996;148:1397-1406.
56. Kambham H, Markowitz GS, Appel GB, et al. Heavy chain deposition disease: the disease spectrum. Am J Kidney Dis. 1999;33:954-962.
57. Cogne M, Silvain C, Khamlichi AA, et al. Structurally abnormal immunoglobulins in human immunoproliferative disorders. Blood. 1992;79:2181-2195.
58. Gertz MA, Kyle RA. Amyloidosis (AL). In: Wiernik PH, Goldman JM, Dutcher JP, et al, eds. Neoplastic Diseases of the Blood. 4th ed. Cambridge, UK: Cambridge University Press; 2003:595-618.
59. Rukavina JG, Block WD, Jackson CE, et al. Primary systemic amyloidosis: a review and an experimental, genetic, and clinical study of 29 cases with particular emphasis on the familial form. Medicine (Baltimore). 1993;72:45-63.
60. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32: 45-59.
61. Serpell LC, Sunde M, Blake CCF. The molecular basis of amyloidosis. Cell Mol Life Sci. 1997;53:871-887.
62. Solomon A, Weiss DR, Murphy C. Primary amyloidosis associated with a novel heavy-chain fragment (AH amyloidosis). Am J Hematol. 1994;45:171-176.
63. Preud'Homme J-L, Aucouturier P, Touchard G, et al. Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains. Kidney Int. 1994;46:965-972.
64. Ferrario F, Rastaldi MP. Histopathological atlas of renal diseases: light chain deposition disease. J Nephrol. 2005;18:499-502.
65. Fermand J-P, Brouet J-C. Heavy chain diseases. Hematol Oncol Clin North Am. 1999;13:1281-1294.
66. Wahner-Roedler D, Kyle RA. Heavy-chain disease. In: Wiernik PH, Goldman JM, Dutcher JP, et al, eds. Neoplastic Diseases of the Blood. 4th ed. Cambridge, UK: Cambridge University Press; 2003: 573-594.
67. Dispenzieri A, Gertz MA. Cryoglobulinemia, heavy chain diseases and monoclonal gammopathy-associated disorders. In: Greer JP, Foerster J, Lukens JN, et al, eds. Wintrobe's Clinical Hematology. 11th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2004:2683-2694.
68. Wahner-Roedler DL, Kyle RA. Mu-heavy chain disease: presentation as a benign monoclonal gammopathy. Am J Hematol. 1992;40: 56-60.